Supartz
PMA P980044
Active
Valid until
No expiry
FDA recalls
None found
Documents
Trust
Regulatory status
| Region | Authorization | Number | Date | Status |
|---|---|---|---|---|
| United States | FDA PMAAPPR | NumberP980044 | Date24 Jan 2001 | StatusActive |
Official records
- FDA PMA database P980044
From the FDA record
FDA PMA P980044
- Received by the FDA
- 1 Dec 1998
- FDA decision
- 24 Jan 2001
- FDA review time
- 785 days from receipt to decision
- Docket number
- 01M-0342
APPROVAL FOR THE SUPARTZ(TM) DISPO. THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.
Coverage
- Active
- Expiring
- Withdrawn
- Listed
- Not covered
United States — FDA PMA Active
Specification
- Trade name
- Supartz Fx
- Generic name
- Acid, hyaluronic, intraarticular
- PMA number
- FDA product code
- MOZ
- Device class
- Class III
- Advisory committee
- Orthopedic
- FDA decision
- APPR Approved
Overview
AI-generated summary, 18 Sep 2026
Supartz is a hyaluronic acid intraarticular injection indicated for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, such as acetaminophen. It is supplied as a sterile, single-use product for intraarticular administration.
The device is manufactured by Seikagaku Corp. and received FDA PMA approval (P980044) on January 24, 2001. It is intended for use in device class 3 and is indicated specifically for intraarticular use in the knee joint for osteoarthritis pain management.
Devices cleared under P980044
Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.
| UDI-DI | Size and differences | |||
|---|---|---|---|---|
| Supartz | NA | 05060459970120 | — | On the market |
| Supartz | None | 05060548950057 | — | On the market |
| SUPARTZ FX sodium hyaluronate 71564444 | 71564444 | 10389130444418 | — | On the market |
| SUPARTZ FX sodium hyaluronate 89130-4444-1 | 7156-4444 / 89130-4444-1 | M717715644440 | — | No longer on the market |
| SUPARTZ® sodium hyaluronate 89130-5555-01 | 7156-5555 / 89130-5555-01 | M717715655550 | — | No longer on the market |
| VISCO-3 sodium hyaluronate 00-1111-001-03 | 00-1111-001-03 / 00-1111-001-03 | 04987541301314 | — | On the market |
Similar devices
Other devices filed under FDA product code MOZ (Acid, Hyaluronic, Intraarticular).
- GenVisc 850 by Channel-Markers Medical, LLC
- Hymovis High Molecular Weight Viscoelastic Hyaluronan by Fidia Farmaceutici
- Orthovisc High Molecular Weight Hyaluronan by Anika Therapeutics, Inc.
- Hyalgan Acid, Hyaluronic, Intraarticular by Fidia Farmaceutici S.p.A.
- Euflexxa (1% Sodium Hyaluronate) by Ferring Pharmaceuticals, Inc.
- Durolane by BIOVENTUS LLC
- Gel-Syn Acid, Hyaluronic, Intraarticular by Ibsa Institut Biochimique SA
- Monovisc Injectable Intra-Articular Device by Anika Therapeutics, Inc.
- SYNOJOYNT by Mesoblast
- TriVisc by Channel-Markers Medical, LLC